NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
Clinical Trials
9 trialsNCT04623541 2026-03-04
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT04542824 2026-03-03
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT06564038 2026-02-05
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT03384654 2025-05-25
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT03059615 2020-07-31
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS
Immune System Key Ltd
Phase 2 Withdrawn